Compare BioNTech SE - ADR (BNTX) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Flux Power Holdings Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Flux Power Holdings Inc trades at $0.57 (market cap $11.23M). The key difference: BioNTech SE - ADR is far larger — about 2075.7× Flux Power Holdings Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BNTX | FLUX | |
|---|---|---|
Market Cap | $23.31B | $11.23M |
Sector | Health | Utilities |
52-Week High | $119.34 | $6.66 |
52-Week Low | $83.89 | $0.51 |
Enterprise Value | $6.60B | $17.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
FLUX trades at $0.5702, up 8.82% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The company reported mixed quarterly results, missing EPS estimates in Q3 2025 and Q1 2026 while beating in Q4 2025. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 6 buy ratings. Recent developments include the upcoming Q4 2026 earnings call and the launch of SkyEMS 3.0 with AI-powered fleet insights.
FLUX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish sentiment from Wall Street contrasts with persistent losses and negative ROE/ROA. Key catalysts include execution on new product launches and path to profitability, while risks involve sustained cash burn and competitive pressure in clean energy storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
